Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05318105 · ClinicalTrials.gov registry record · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
A NA study of Heart Failure and Fluid Overload, sponsored by Nuwellis.
- Recruiting
- Registry status
- NA
- Development phase
- 372
- Enrollment target
- 17
- Study locations
NCT05318105: Recruiting NA study of Heart Failure and Fluid Overload, sponsored by Nuwellis.
NCT05318105 is a NA study of Heart Failure and Fluid Overload that is actively recruiting participants, run by Nuwellis. The registered enrollment target is 372 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (82% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05318105, a NA study of Heart Failure and Fluid Overload, is actively recruiting participants, sponsored by Nuwellis.
- RECRUITING
- Registry status
- NA
- Development phase
- 372 participants
- Enrollment target
- 17
- Study locations
Study Summary
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Primary Outcome
Heart Failure (HF) event defined as any HF rehospitalization or unplanned use of IV loop diuretics, vasoactive medications or Aquadex therapy in any outpatient setting.
Conditions Studied
Interventions
- DEVICE Aquadex Smartflow® System
- DRUG IV Loop Diuretics
Study Locations (17)
California
- MemorialCare, Long Beach Medical Center - Long Beach
- Sharp Memorial Hospital, San Diego Cardiac Center - San Diego
- University of California San Francisco - San Francisco
New York
- Mount Sinai Morningside - New York
- The Mount Sinai Hospital - New York
- Northwell Health - New York
Florida
- BayCare Medical Group, Morton Plant - Clearwater
- St. Joseph's Hospital - Tampa
Ohio
- The Christ Hospital - Cincinnati
- The Ohio State University - Columbus
Arizona
- Banner Health - Tucson
Kentucky
- University of Kentucky - Lexington
Michigan
- Henry Ford Health - Detroit
Pennsylvania
- Abington Jefferson Health - Abington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05318105 shows while recruiting
NCT05318105 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (82% lower).
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Aquadex Smartflow® System is the first listed.
NCT05318105 lists 17 locations in 11 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT05318105 about?
NCT05318105 is a clinical study titled "Ultrafiltration Versus IV Diuretics in Worsening Heart Failure". The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
What is the current status of trial NCT05318105?
This trial is currently recruiting. It is a NA study. The enrollment target is 372 participants. The study started on 2022-06-28. Estimated completion is 2026-12-31.
What conditions does trial NCT05318105 study?
This clinical trial studies the following conditions: Heart Failure, Fluid Overload, Heart Failure (for Example, Fluid Overload).
What interventions are being tested in trial NCT05318105?
The interventions under investigation include: Aquadex Smartflow® System (DEVICE), IV Loop Diuretics (DRUG).
Who is sponsoring clinical trial NCT05318105?
This trial is sponsored by Nuwellis, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05318105 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05318105's enrollment target sits among peer trials
372 120th of 397 higher than 278 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- NCT06976801 · 372 participants · NA
Tibial IMN Vs. Tibial Micromotion IMN
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI